Financial Performance - The company recorded a net loss attributable to shareholders of approximately HKD 22,311,263 for the six months ended June 30, 2022, compared to a profit of HKD 370,288 in the same period last year, resulting in a loss per share of HKD 0.82[6]. - Revenue for the six months ended June 30, 2022, was HKD 318,670,000, a decrease of 61.2% compared to HKD 822,403,000 for the same period in 2021[46]. - The company reported a loss before tax of HKD 22,629,452, compared to a profit of HKD 1,279,078 in the previous year[46]. - Total comprehensive loss attributable to equity holders for the period was HKD 22,311,263, compared to a profit of HKD 370,288 in the same period last year[46]. - The loss per share for the six months ended June 30, 2022, was HKD 0.82, compared to earnings of HKD 0.02 per share in the prior year[46]. - The company reported a total comprehensive loss of HKD 22,311,263 for the six months ended June 30, 2022, compared to a total comprehensive income of HKD 370,288 for the same period in 2021[86]. Investment Activities - The company terminated a biotechnology project in June 2022 after investing HKD 20,000,000 due to unfavorable investment conditions and risks[11]. - The company plans to maintain a prudent approach in identifying and evaluating investment opportunities while actively seeking long-term investment prospects[14]. - The company aims to balance investments between listed and unlisted securities to enhance shareholder returns, reflecting changes in market and economic conditions[11]. - The company raised approximately HKD 15,720,000 from a placement for potential investments related to biotechnology projects[11]. - The company is closely monitoring market economic and financial conditions to seek suitable investment opportunities[11]. Financial Position - As of June 30, 2022, the group's cash, bank balances, and cash amounted to approximately HKD 2,560,000, a decrease from HKD 26,600,000 as of December 31, 2021[16]. - Total borrowings of the group as of June 30, 2022, were approximately HKD 280,000, down from HKD 700,000 as of December 31, 2021[16]. - The group's capital debt ratio was approximately 0.26% as of June 30, 2022, compared to 0.58% as of December 31, 2021[16]. - The net amount of financial asset investments was approximately HKD 79,150,000 as of June 30, 2022, down from HKD 100,170,000 as of December 31, 2021[16]. - Cash and cash equivalents decreased significantly to HKD 2,561,021 from HKD 26,643,975 at the end of the previous year[55]. - Current assets decreased to HKD 105,247,707 from HKD 128,340,397 as of December 31, 2021[49]. - Current liabilities decreased to HKD 280,920 from HKD 744,158 year-on-year[49]. - Net assets decreased to HKD 104,302,837 from HKD 126,614,100 as of December 31, 2021[49]. Employee Costs - Total employee costs during the review period were HKD 1,795,490, an increase from HKD 1,636,100 in the previous year[23]. - Employee costs, including directors' remuneration, increased to HKD 1,750,240 for the six months ended June 30, 2022, from HKD 1,592,600 in the same period of 2021, representing an increase of approximately 9.9%[75]. Dividends - The company did not declare any interim dividend for the period ended June 30, 2022, consistent with the previous year[7]. - The company did not declare an interim dividend for the period[46]. - The company did not declare any interim dividends for the current and prior periods, maintaining a dividend of zero for both periods[89]. Fair Value and Financial Instruments - Realized and unrealized losses on financial assets at fair value through profit or loss increased to approximately HKD 10,030,000 and HKD 8,810,000, respectively, compared to realized gains of HKD 1,850,000 and unrealized gains of HKD 2,720,000 in the previous year[8]. - The company reported a fair value loss of approximately HKD 9,470,000 on listed securities, compared to a gain of HKD 3,130,000 in the previous year[8]. - The fair value loss on financial assets at fair value through profit or loss was HKD (18,841,845) for the six months ended June 30, 2022, compared to a gain of HKD 4,573,746 for the same period in 2021[73]. - The fair value of listed equity securities was HKD 75,878,348 as of June 30, 2022, down from HKD 97,556,902 as of December 31, 2021, reflecting a decrease of approximately 22.2%[89]. - The fair value of financial assets measured at fair value through profit or loss increased to HKD 90,191,955 as of June 30, 2022, compared to HKD 86,731,770 as of June 30, 2021[118]. - The total fair value of financial instruments measured at fair value as of June 30, 2022, was HKD 79,150,073, which includes HKD 75,878,348 in level 1 and HKD 3,271,725 in level 3[111]. - The fair value of non-listed equity securities was recorded at HKD 3,271,725 as of June 30, 2022[111]. - The company’s financial instruments are classified into three levels based on the observability of inputs used in the valuation[110]. - The financial instruments' fair value measurement utilized significant unobservable inputs, indicating a lack of market liquidity[123]. - The carrying amount of other financial instruments measured at cost did not differ materially from their fair value as of June 30, 2022[124]. - The company reported no transfers between fair value measurement levels during the six months ended June 30, 2022[123]. - The fair value measurement techniques employed were consistent with prior periods, ensuring comparability[123]. - The company’s financial assets included significant unobservable inputs, highlighting potential valuation risks[123]. Market Conditions - Concerns over rising inflation and geopolitical tensions continue to impact market outlook, with the Chinese government setting a GDP growth target of 5.5% for 2022[13].
鼎立资本(00356) - 2022 - 中期财报